Related references
Note: Only part of the references are listed.A phase 2 trial of single low doses of rasburicase for treatment of hyperuricemia in adult patients with acute leukemia
Pankit Vachhani et al.
LEUKEMIA RESEARCH (2021)
Efficacy of Single Dose Rasburicase (1.5mg) for Prophylaxis and Management of Laboratory Tumor Lysis Syndrome
Ashwin Philips et al.
INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION (2018)
Efficacy of Single Dose Rasburicase (1.5mg) for Prophylaxis and Management of Laboratory Tumor Lysis Syndrome
Ashwin Philips et al.
INDIAN JOURNAL OF HEMATOLOGY AND BLOOD TRANSFUSION (2018)
The optimal single-dose regimen of rasburicase for management of tumour lysis syndrome in children and adults: a systematic review and meta-analysis
X. Yu et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2017)
Single 4.5mg fixed-dose of rasburicase for hyperuricemia associated with tumor lysis syndrome
Kajal S. Patel et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2017)
Sampling on ice will not yield reliable uric acid monitoring in rasburicase-treated patients
Barbara Depreter et al.
CLINICAL BIOCHEMISTRY (2016)
Fixed, low-dose rasburicase for the treatment or prevention of hyperuricemia in adult oncology patients
Jon D. Herrington et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2015)
Comparative Evaluation of Single Fixed Dosing and Weight-Based Dosing of Rasburicase for Tumor Lysis Syndrome
Ali McBride et al.
PHARMACOTHERAPY (2013)
A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome
S. Vadhan-Raj et al.
ANNALS OF ONCOLOGY (2012)
Effectiveness of a single 3-mg rasburicase dose for the management of hyperuricemia in patients with hematological malignancies
S. M. Trifilio et al.
BONE MARROW TRANSPLANTATION (2011)
Fixed-Dose Rasburicase 6 mg for Hyperuricemia and Tumor Lysis Syndrome in High-Risk Cancer Patients
Ashleigh N. Vines et al.
ANNALS OF PHARMACOTHERAPY (2010)
Control of Plasma Uric Acid in Adults at Risk for Tumor Lysis Syndrome: Efficacy and Safety of Rasburicase Alone and Rasburicase Followed by Allopurinol Compared With Allopurinol Alone-Results of a Multicenter Phase III Study
Jorge Cortes et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Effective treatment and prophylaxis of hyperuricemia and impaired renal function in tumor lysis syndrome with low doses of rasburicase
Margit Hummel et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2008)
Tumour lysis syndrome: new therapeutic strategies and classification
MS Cairo et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
Incidence, medical resource utilisation and costs of hyperuricemia and tumour lysis syndrome in patients with acute leukaemia and non-Hodgkin's lymphoma in four European countries
L Annemans et al.
LEUKEMIA & LYMPHOMA (2003)
Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients with leukemia or lymphoma
CH Pui et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Share Paper
